Martin Jönsson appointed new CEO of AlzeCure Pharma
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the board has appointed Martin Jönsson as new CEO. Current CEO Johan Sandin, who is also one of the founders of AlzeCure Pharma, remains in the company as Chief Scientific Officer (CSO) and will thus continue to be deeply involved in the research and development of the company's portfolio of candidate drugs.Martin Jönsson comes most recently from a